Immune Checkpoint Proteins

 

Category: Biosimilars

Exhibitor: ACROBIOSYSTEMS CO., LTD.

Booth No: M1033

 

Characteristic

 

Immune checkpoint proteins are key regulators of immune response against threats while preserving self-tolerance. The classic immune checkpoint consists of co-inhibitory receptors (CTLA-4, PD-1, TIGIT, LAG-3), which inhibit T-cell function and co-stimulatory receptors (GITR, 4-1BB, OX40, CD40) which stimulate T cell activation. Research on the co-inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte antigen 4) and PD-1 (programmed cell death protein 1) showed significantly improved survival rates of patients with metastatic solid tumors after inhibition of these receptor pathways. Therefore, antibody drugs against immune checkpoints for cancer, tumors and other diseases therapeutics is a key mode in cancer therapy.
Product Features:
• High purity verified by MALS or HPLC
• High bioactivity verified by ELISA/SPR/BLI/FACS
• High batch to batch consistency by strict QC tested
Main Applications:
• Antibody binding assay
• Antibody affinity assay
• Neutralizing antibody binding assay
• Cell-based assay
• Pharmacokinetics (PK) analysis

 

Other Products

 

• 

  Bispecific antibody targets and services

• 

  Key Raw Materials for Cell and Gene Therapy

• 

  Multi-pass Transmembrane Proteins and Technology Platforms

• 

  Toolbox for ADC Targets: the Magic Bullets

• 

  FDA DMF Filed Proteins

• 

  High-quality Fc Receptor Proteins

• 

  Residue Detection kits/

• 

  Star Staining Fluorescent-labeled Products

• 

  GMP Grade Solutions for Cell Therapy

 

 

 

Back